Modifications to Treatment Plan of Rectal Cancer in Response to COVID-19 at the Philippine General Hospital
10.3393/ac.2021.00381.0054
- Author:
Sofia Isabel T. MANLUBATAN
1
;
Marc Paul J. LOPEZ
;
Mark Augustine S. ONGLAO
;
Hermogenes J. MONROY III
Author Information
1. Division of Colorectal Surgery, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines
- Publication Type:Original Article
- From:Annals of Coloproctology
2021;37(4):225-231
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:The coronavirus disease 2019 (COVID-19) pandemic has strained healthcare resources worldwide. Despite the high number of cases, cancer management should remain one of the priorities of healthcare, as any delay would potentially cause disease progression.
Methods:This was an observational study that included nonmetastatic rectal cancer patients managed at the Philippine General Hospital from March 16 to May 31, 2020, coinciding with the lockdown. The treatment received and their outcomes were investigated.
Results:Of the 52 patients included, the majority were female (57.7%), belonging to the age group of 50 to 69 years (53.8%), and residing outside the capital (59.6%). On follow-up, 23.1% had no disease progression, 17.3% had local progression, 28.8% had metastatic progression, 19.2% have died, and 11.5% were lost to follow up. The initial plan for 47.6% patients was changed. Of the 21 patients with nonmetastatic disease, 2 underwent outright resection. The remaining 19 required neoadjuvant therapy. Eight have completed their neoadjuvant treatment, 8 are undergoing treatment, 2 had their treatment interrupted, and 1 has yet to begin treatment. Among the 9 patients who completed neoadjuvant therapy, only 1 was able to undergo resection on time. The rest were delayed, with a median time of 4 months. One has repeatedly failed to arrive for her surgery due to public transport limitations. There was 1 adjuvant chemotherapy-related mortality.
Conclusion:Delays in cancer management resulted in disease progression in several patients. Alternative neoadjuvant treatment options should be considered while taking into account oncologic outcomes, acceptable toxicity, and limitation of potential COVID-19 exposure.
